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Introduction
Cancer is one of the most dreaded diseases of the 20th century.   
It is the single most common cause of deaths and spreading fur-
ther with continuance in 21st century in both developed and 
developing  countries.1,2  Statistics  show  that  men  are  largely 
plagued by lung, colon, rectal and prostate cancer, while women 
increasing suffer from breast, stomach, colon and rectal cancer. 
From literature it is revealed that many natural products are avail-
able  as  chemo-preventive  agents  against  commonly  occurring 
cancer types. However, there is continuing need for identifica-
tion, characterization and development of new chemo-preventive 
agents from enormous pool of synthetic, biological and natural 
products.
About 60% of currently used anticancer agents are obtained 
from natural sources, including plants, marine organisms and 
microorganisms. Fungal toxins (mycotoxins) though known to 
be toxic to the animal and human systems still find their use 
in therapeutic application. Mycophenolic acid,3 penicillic acid,4 
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5-methoxy-sterigmatocystin,5  a  series  of  analogues  of  anguid-
ine,6,7  including  triacetoxyscirpenol,  three  diacetoxyscirpenols, 
three monoacetoxyscirpenol and scirrpenol, T-2 toxin and and 
related  tricocethecenes,8  cytochalasin  B,9  patulin,10  aflastatin 
A,11 14-Hydromytoxin B and 16-Hydroxyroridin E,12 tenuazonic 
acid,13 4-beta-acetoxyscirpendiol,14 gliotoxin,15 fluorinated pseu-
rotin A, synerazol,16 rubratoxin B,17 beauvericin18 showed anti-
tumor activities in different types of cancer cell line and in vivo. 
Harri et al. reported that the trichothecenes verrucarins A and B 
and roridin A inhibited the growth of Ehrlich ascites tumor in 
mice and Walker carcinoma in rats. Myrocin C, a new diterpene 
from soil fungus Myrothecium verrucaria increases the life span 
of  EAC-bearing  mice.19  Leuteoskyrin,a  hydroxyanthraquinone 
is proved to inhibit mRNA synthesis in Ehrlich ascites tumor 
cells.20,21 Oxidative stress may be involved in both initiation and 
promotion of multi-step carcinogenesis. Some synthetic,22 bio-
genic chemicals,23 nanoparticals,24 phytochemicals25,26 can pre-
vent oxidative stress22,23 and thus can modulate the expression of 
genes related to tumor promotion.
Many fungal toxins exhibit in vitro and in vivo antineoplastic effects on various cancer cell types. Luteoskyrin, a hydroxyan-
thraquinone has been proved to be a potent inhibitor against ehrlich ascites tumor cells. The comparative antitumor 
activity and antioxidant status of MT81 and its structural analogue [acetic acid-MT81 (aa-MT81)] having polyhydroxyan-
thraquinone structure were assessed against ehrlich ascites carcinoma (eac) tumor in mice. The in vitro cytotoxicity 
was measured by the viability of eac cells after direct treatment of the said compounds. In in vivo study, MT81 and its 
structural analogue were administered (i.p.) at the two different doses (5, 7 mg MT81; 8.93, 11.48 mg aa-MT81/kg body 
weight) for 7 days after 24 hrs. of tumor inoculation. The activities were assessed using mean survival time (MsT), in-
creased life span (ILs), tumor volume, viable tumor cell count, peritoneal cell count, protein percentage and hematological 
parameters. antioxidant status was determined by malondialdehyde (MDa) and reduced glutathione (Gsh) content, and 
by the activity of superoxide dismutase (sOD) and catalase (caT). MT81 and its structural analogues increased the mean 
survival time, normal peritoneal cell count. They decreased the tumor volume, viable tumor cell count, hemoglobin per-
centage and packed cell volume. Differential counts of WBc, total counts of RBc & WBc that altered by eac inoculation, 
were restored in a dose-dependent manner. Increased MDa and decreased Gsh content and reduced activity of sOD, 
and catalase in eac bearing mice were returned towards normal after the treatment of MT81 and its structural analogue. 
Being less toxic than parent toxin MT81, the structural analogue showed more prominent antineoplastic activities against 
eac cells compared to MT81. at the same time, both compounds exhibit to some extent antioxidant potential for the 
eac-bearing mice.62  Oxidative Medicine and cellular Longevity  Volume 3 Issue 1
In vivo treatment of MT81 and AaMT81 inhibit growth 
of EAC cells. The result in Figures 1 and 2 indicates that con-
trol EAC-bearing mice (EAC and vehicle control groups) had a 
gradual increase in body weight of about 22 to 24 gm in 21 days 
from the day zero. When compared to the body weight of con-
trol EAC-bearing mice on day 21, the body weight of the treated 
mice decreased significantly by about 50%, indicating the effect 
of MT81 and Aa-MT81 in preventing the growth of Ehrlich 
ascites tumor cells. Inhibition of tumor growth in vivo expressed 
by the mean survival time and 30 days survivor has been sum-
marized in Table 1. In case of EAC control, mean survival time 
is 15.66 ± 1.667 (all died by 20 days) whereas with high dose of   
(7  mg/kg  of  body  weight)  of  MT81,  mean  survival  time  is   
28.5  ±  1.138  days  indicating  89.1%  increase  in  longevity   
(Table  1)  of  the  treated  group  with  respect  to  EAC  control. 
Aa-MT81 have demonstrated enhanced effect on the mean life 
span by 59.3%. The decrease in body weight in toxin-treated mice 
has been shown in Figures 1 and 2. The effects of MT81 and 
its structural analogue at different doses on tumor volume and 
viable tumor cell count are shown in Figures 4 and 5. MT81 and 
Aa-MT81 reduced the tumor volume, viable tumor cell count, 
packed cell volume (Fig. 11), and protein percent (Fig. 12).
Effect on normal peritoneal cells. The average number of 
peritoneal exudates cells in normal mice was found to be 5.3 ± 
0.248 x 106. Treatment of MT81 and its two derivatives increase 
the number of peritoneal cells significantly compared to the vehi-
cle control group (Fig. 6).
Hematological  parameters.  Hematological  parameters 
of  EAC-bearing  mice  on  day  14  were  found  to  be  signifi-
cantly changed from normal (saline control) group (Table 2,   
Figs. 7–10). Hemoglobin content and RBC count in the EAC 
and vehicle control group were significantly (p ≤ 0.01) decreased 
in  comparison  to  the  normal  group.  MT81  increased  the 
hemoglobin content and RBC counts to a less extent whereas 
Aa-MT81  increased  them  significantly  (p  <  0.05).  The  total 
WBC counts and protein were found to be increased significantly 
in the vehicle control group (p < 0.01). Administration of MT81 
and its structural analogue at the above said doses reduces the 
WBC counts and protein as compared to the vehicle control.   
Mycotoxin MT81 was isolated, purified and identified in our 
laboratory from a locally isolated fungal strain of Penicillium nig-
ricans (patent no. 156916 dated 15.2.82, Govt. of India). MT81 
is a dextrorotatory polyhydroxyanthraquinone compound hav-
ing molecular formula of C22H18O7 and molecular wt. of 394.27   
Its LD50 value is 35.1 mg/Kg body wt. in mice. MT81 is a good 
hyperglycemic,28  antimicrobial29  and  antileishmanial30  agents.   
It  produces  massive  bone  marrow  depression,31  liver,32  brain33 
and kidney34 dysfunction. MT81 exhibits central nervous system 
depressant action.35 MT81 has shown in vitro and in vivo antitu-
mor activity against Ehrlich ascites tumor cells.36
To generate more potent and less toxic toxin, a structural 
analogue, acetic acid (Aa-MT81) MT81 was synthesized in our 
laboratory having LD50 value 80.4 mg/kg body weight in mice. 
This analogue was reported to possess antimicrobial29 and anti-
leishmanial30 effects. The Ehrlich ascites tumor cell (EAC) is 
a spontaneous murine mammary adenocarcinoma1 and carried 
out in inbred mice by serial intraperitoneal (i.p.) administra-
tion.  As  (-)-luteoskyrin  and  (+)-rugulosin  being  hydroxyan-
thraquinone  possess  antitumor  properties,  present  study  was 
carried out to evaluate the antitumor and antioxidant activities 
of MT81 and its structural analogue (which are also polyhy-
droxyanthraquinone) against Ehrlich ascites carcinoma (EAC) 
in mice.
Results
Short-term (in vitro) cytotoxicity. The in vitro cytotoxicity of 
MT81 and its structural analogue towards EAC cells showed that 
the IC50 of MT81, Aa-MT81 were 17 µg, 22 µg/ml respectively. 
The degree of in vitro lethality is slightly more in case of MT81 
due to its toxicity.
Mean survival time (MST). In the EAC control group, the 
mean survival time was 16.0 ± 1.75 days, while it increased to 24.0 
± 1.67 (3.88 mg/kg), 28.5 (5 mg/kg) days in the MT81-treated 
groups, 23.0 ± 1.62 (8.93 mg/kg), 25.9 ± 1.38 (11.48 mg/kg) 
days in the Aa-MT81-treated groups respectively. These results 
are almost comparable to that for 5-fluorouracil (20 mg/kg), the 
standard drug, for which the MST was 40.2 ± 1.08 days.
Table 1. Mean survival time and increased life span of eac-bearing mice after the treatment of MT81 and acetic acid-MT81
Group
EAC challenge cell 
no./mouse
Mean survival time 
(days) Mean ± SEM
Increase in life 
span (%)
30 days   survivors/
total no.
saline control (0.9% Nacl w/v) - - - 6/6
eac control 2 × 106 15.66 ± 1.67 0.0 0/6
Vehicle control (0.01 ml propylene glycol/20 gm 
of body weight)
2 × 106 16.0 ± 1.75 2.17a 0/6
MT81 low dose (5 mg/kg body weight) 2 × 106 24.0 ± 1.67* 50b 1/6
MT81 high dose (7 mg/kg body weight) 2 × 106 28.5 ± 1.14* 78.12b 1/6
aa-MT81 low dose (8.93 mg/kg body weight) 2 × 106 23.0 ± 1.65* 43.75b 1/6
aa-MT81 high dose (11.48 mg/kg body weight) 2 × 106 25.90 ± 1.38* 61.88b 1/6
5-Fluorouracil (20 mg/kg body weight) 2 × 106 40.2 ± 1.08* 151.25b 5/6
Data given are Mean ± seM; n = 6. *significant different at p < 0.05, **significant different at p < 0.01, ***significant different at p < 0.001; eac control 
and Vehicle control are compared to saline control; Treated groups are compared to Vehicle control by one-way aNOVa followed by student’s 
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In EAC-bearing mice, a regular rapid increase in ascites tumor 
volume is seen. Ascites fluid is the direct nutritional source for 
tumor cell and so a rapid increase of this fluid is very necessary 
factor for tumor growth and nutrition. An anticancer drug is con-
sidered reliable if it can prolong the life span of animals.37 MT81 
and its Acetic acid analogue decrease the ascites fluid volume, 
viable EAC cell count and increase the percentage of life span. 
There was a decrease in lymphocytes in malignancy, accompa-
nied by an increase in neutrophils. The treatment changed those 
altered parameters significantly (p < 0.01), to near normal in a 
dose-dependent manner.
Lipid peroxidation and glutathione content. As shown in 
Figure 14, the levels of lipid peroxidation in liver tissue were sig-
nificantly increased in EAC and vehicle control group as compare 
to the normal group (p < 0.01). After administration of MT81 
and its Acetic acid analogue to EAC bearing mice the levels of 
lipid peroxidation were reduced respectively as compared to EAC 
and vehicle control. Inoculation with EAC drastically decreased 
the GSH content in vehicle control group in comparison to nor-
mal  group.  The  administration  of  Aa-MT81  increased  GSH 
level in a dose dependent manner compared to MT81 but not 
significantly.
Effect on antioxidant enzymes. The activities of superoxide 
dismutase and catalase in the livers of EAC bearing mice decreased 
in EAC and vehicle control groups (p < 0.05). Treatment with 
MT81 and its structural analogue increased these enzyme activities 
to some extent but not in a significant manner (Figs. 16 and 17).
Discussion
The  present  study  was  carried  out  to  evaluate  the  antitumor 
effect and antioxidant status of mycotoxin MT81 and its struc-
tural analogue in EAC-bearing mice. The treated animals sig-
nificantly inhibited the tumor volume, packed cell volume, viable 
tumor cell count, increased the mean survival time, peritoneal 
cell count. They also restored the hematological parameters to 
more or less normal levels. They decreased the hepatic lipid per-
oxidation and increased the antioxidant enzyme SOD and CAT 
as well as the GSH level.
Figure 1. Inhibitory role of MT81 on the body weight change in eac-
bearing mice. Data given are Mean ± SEM; n = 6. *significant different 
at p < 0.05, **significant different at p < 0.01, ***significant different at 
p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 2. Inhibitory role of aaMT81 on the body weight change of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 3. Modulatory role of MT81 and aaMT81 on Mean survival 
Time of eac-bearing mice. Data given are Mean ± SEM; n = 6. *signifi-
cant different at p < 0.05, **significant different at p < 0.01, ***sig-
nificant different at p < 0.001; EAC Control and Vehicle Control are 
compared to saline control; Treated groups are compared to Vehicle 
control by one-way aNOVa followed by student’s t-test.64  Oxidative Medicine and cellular Longevity  Volume 3 Issue 1
or myelopathic conditions.39 Administration of Acetic acid ana-
logue by restoring hemoglobin content, RBC and WBC count 
towards normal exhibit its protective role on hemopoietic system 
compared to its parent toxin, MT81. The hematological param-
eter showed that hemoglobin content and total RBC count were 
found to be lower in case of EAC control group in comparison 
with saline control. Most of the cases of low doses of the toxins, 
the values are found to be less significant. But in case of high 
dose of Aa-MT81, significant increase in hemoglobin content 
and RBC count were observed but which were not seen in case of 
high dose of MT81, most probably due to its higher toxicity than 
Acetic acid analogue. The toxin treated animals showed com-
paratively lower total WBC count than EAC and vehicle control. 
It may be due to the tumorocidal activity of the toxins.
Cancer is considered as a multifactor disease, where oxida-
tive stress may be involved in both initiation and promotion of 
multi-step carcinogenesis. Reactive oxygen species (ROS) can 
accelerate  DNA  damage,  stimulate  pro-carcinogenesis,  initi-
ate  lipid  peroxidation,  inactivate  antioxidant  enzyme  systems 
and thus can modulate the expression of genes related to tumor 
promotion.40,41
Excessive  production  of  free  radicals  cause  macromo-
lecular  damage  and  can  induce  lipid  peroxidation  in  vivo.42 
Malondialdehyde  (MDA)  the  end  product  of  lipid  peroxida-
tion, are seen to be higher in cancer tissues than in non-diseased 
organ.43 GSH, an important non-protein thiol, plays a significant 
role in protecting cells by scavenging ROS44 and potent inhibi-
tor of the neoplastic process. Aa-MT81 significantly decreased 
the lipid peroxidation compared to MT81 by reducing the MDA 
By decreasing the ascites fluid volume and arresting the tumor 
growth these toxins increase the life span of EAC bearing mice.
Myelosupression and anemia are the major outcome after can-
cer chemotherapy.38 In tumor-bearing mice, anemia occurs due 
to the diminution in RBC or hemoglobin percentage, and these 
may happens either due to iron deficiency or due to hemolytic 
Figure 5. Inhibition of Viable Tumor cell count of eac-bearing mice 
by MT81 and aaMT81 on Data given are Mean ± SEM; n = 6. *significant 
different at p < 0.05, **significant different at p < 0.01, ***significant 
different at p < 0.001; eac control and Vehicle control are compared 
to saline control; Treated groups are compared to Vehicle control by 
one-way aNOVa followed by student’s t-test.
Figure 6. Increase of Peritoneal cell count of eac-bearing mice by 
MT81 and aaMT81 on. Data given are Mean ± SEM; n = 6. *significant 
different at p < 0.05, **significant different at p < 0.01, ***significant 
different at p < 0.001; eac control and Vehicle control are compared 
to saline control; Treated groups are compared to Vehicle control by 
one-way aNOVa followed by student’s t-test.
 Figure 4. Inhibition of Tumor Volume of eac-bearing mice by MT81 
and aaMT81. Data given are Mean ± SEM; n = 6. *significant different at 
p < 0.05, **significant different at p < 0.01, ***significant different at p 
< 0.001; oryeac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.www.landesbioscience.com  Oxidative Medicine and cellular Longevity  65
level but the glutathione content is not increased significantly in a 
dose-dependent manner most probably due to their toxicity.
SOD  and  CAT,  the  antioxidant  enzymes  prevent  H2O2-
mediated intracellular damage, which is thought to be prereq-
uisite for carcinogenesis.45  SOD  dismutates  superoxide anions 
(O2
-) to H2O2 and protects the cells against (O2
-)-mediated lipid 
peroxidation. CAT acts on H2O2 by decomposing it, thereby 
neutralizing its toxicity. Gupta et al. demonsrated that reduction 
in several antioxidant defense mechanisms correlates with the 
emergence of the malignant phenotype.46 Consistent with this, a 
diminution in SOD activity in EAC-bearing mice may be due to 
the loss of Mn2+-containing SOD activity in EAC cells and loss of 
mitochondria, leading to a decrease in total SOD activity in the 
liver.47 A small amount of catalase in tumor cells was reported.48 
The inhibitions of SOD and CAT to some extent activities as 
a result of tumor growth were reported.49 Similar findings were 
observed in the present study with EAC-bearing mice. The treat-
ment of MT81 and Aa-MT81 at different doses increased the 
SOD and CAT levels to some extent in a dose-dependent manner 
like the chemopreventive efficacy of perillyl alcohol probably due 
to the inhibition of oxidative stress responses50 and the structural 
analogue showed more potentiality.
The in vitro cytotoxicity and the significant inhibition of in 
vivo growth of EAC cells, increase in life span and of the tumor-
bearing mice confirm the antitumorogenic effect of MT81 and 
its acetic acid derivative against EAC cells (Fig. 17).
Being less toxic than parent toxin MT81, the Acetic acid ana-
logue showed more prominent antineoplastic activities against 
EAC cells compared to MT81. At the same time both exhibit 
mild antioxidant potential for the EAC bearing mice in spite of 
their different toxic side effects.
Table 2. Modulatory role of MT81 and acetic acid-MT81 on the haematological parameters of eac-bearing mice
Group Haemoglobin conc. (g%) Total RBC (x106/mm3) Total WBC (x103/mm3)
saline control (0.9% Nacl w/v) 8.9 ± 0.19 2.9 ± 0.12 7.6 ± 0.15
eac control 6.8 ± 0.20 1.9 ± 0.07 8.6 ± 0.17
Vehicle control (0.01 ml propylene glycol/20 gm 
of body weight)
7.0 ± 0.12 2.0 ± 0.15 8.5 ± 0.15
MT81 low dose (5 mg/kg body weight) 7.3 ± 0.24 2.2 ± 0.12 8.2 ± 0.19
MT81 high dose (7 mg/kg body weight) 7.4 ± 0.11 2.3 ± 0.12 8.09 ± 0.11*
aa-MT81 low dose (8.93 mg/kg body weight) 7.4 ± 0.31 2.4 ± 0.07 8.4 ± 0.10
aa-MT81 high dose (11.48 mg/kg body weight) 7.75 ± 0.21* 2.5 ± 0.04* 8.19 ± 0.17**
Data given are Mean ± seM; n = 6. *significant different at p < 0.05, **significant different at p < 0.01, ***significant different at p < 0.001; eac control 
and Vehicle control are compared to saline control; Treated groups are compared to Vehicle control by one-way aNOVa followed by student’s 
t-test.
Figure 7. Modulatory role of MT81, aaMT81 on Neutrophil count of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 8. Modulatory role of MT81, aaMT81 on eosinophil count of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.66  Oxidative Medicine and cellular Longevity  Volume 3 Issue 1
Figure 9. Modulatory role of MT81, aaMT81 on Lymphocyte count of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 10. Modulatory role of MT81, aaMT81 on Monocyte count of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 11. Role of MT81, aaMT81 on Packed cell Volume (PcV) of 
eac-bearing mice. Data given are Mean ± SEM; n = 6. *significant differ-
ent at p < 0.05, **significant different at p < 0.01, ***significant different 
at p < 0.001; eac control and Vehicle control are compared to saline 
control; Treated groups are compared to Vehicle control by one-way 
aNOVa followed by student’s t-test.
Figure 12. Role of MT81, aaMT81 on Proteins% of eac-bearing mice. 
Data given are Mean ± SEM; n = 6. *significant different at p < 0.05, 
**significant different at p < 0.01, ***significant different at p < 0.001; 
eac control and Vehicle control are compared to saline control; 
Treated groups are compared to Vehicle control by one-way aNOVa 
followed by student’s t-test.www.landesbioscience.com  Oxidative Medicine and cellular Longevity  67
Figure 13. MDa content of eac-bearing mice after the treatment 
of MT81 and aaMT81. Data given are Mean ± SEM; n = 6. *significant 
different at p < 0.05, **significant different at p < 0.01, ***significant 
different at p < 0.001; eac control and Vehicle control are compared 
to saline control; Treated groups are compared to Vehicle control by 
one-way aNOVa followed by student’s t-test.
Figure 14. Glutathione content of eac-bearing mice after the treat-
ment of MT81 and aaMT81. Data given are Mean ± SEM; n = 6. *signifi-
cant different at p < 0.05, **significant different at p < 0.01, ***sig-
nificant different at p < 0.001; EAC Control and Vehicle Control are 
compared to saline control; Treated groups are compared to Vehicle 
control by one-way aNOVa followed by student’s t-test.
Figure 15. sOD activity of eac-bearing mice after the treatment 
of MT81 and aaMT81. Data given are Mean ± SEM; n = 6. *significant 
different at p < 0.05, **significant different at p < 0.01, ***significant 
different at p < 0.001; eac control and Vehicle control are compared 
to saline control; Treated groups are compared to Vehicle control by 
one-way aNOVa followed by student’s t-test.
Figure 16. catalase activity of eac-bearing mice after the treatment 
of MT81 and aaMT81. Data given are Mean ± SEM; n = 6. *significant 
different at p < 0.05, **significant different at p < 0.01, ***significant 
different at p < 0.001; eac control and Vehicle control are compared 
to saline control; Treated groups are compared to Vehicle control by 
one-way aNOVa followed by student’s t-test.68  Oxidative Medicine and cellular Longevity  Volume 3 Issue 1
of Chemical Biology and were maintained by weekly intraperi-
toneal transplantation in the abovesaid mice at the concentra-
tion of 2 x 106/cells/mouse. The EAC cells were harvested after   
7–10 days. The washed cells free of contaminating RBC were 
taken in 0.14 M NaCl solutions. Cells were found to be 99% 
viable by the trypan blue exclusion assay.
Study of in vitro cytotoxicity. Washed and viable EAC cells 
of 7–10 days old tumor were suspended into isotonic solution 
(Phosphate buffer saline) and were adjusted to 1 x 106 cells/ml. 
In a series of test tubes 1 ml of this suspension was taken and 
0.01 ml of varying concentrations (5 to 25 µg) of MT81 and 
Aa-MT81 were added. One tube was kept as EAC control and in 
another tube marked as vehicle control, 0.01 ml of propylene gly-
col was added. The tubes were mildly shaken to mix the contents 
and incubated at 37°C for 3 hr under a CO2 atmosphere. After 
3 hours, percentage of viability of EAC cells was determined by 
trypan blue exclusion method.51
Assessment of in vivo antitumor activity. Male albino mice   
were  divided  into  nine  groups  each  group  containing  twelve. 
Washed and viable EAC cells were resuspended in normal saline 
and inoculated (0.2 ml of 2 x 106 cells/mouse) to animals of all 
groups intraperitoneally except the normal group. After 24 hrs,   
5  ml/kg/day  of  normal  saline  were  administered  in  Group  1 
(Normal) and Group 2 (EAC control) and propylene glycol was 
administered in Group 3 (vehicle control group). MT81 (5 and 
7.00 mg/kg/day), Aa-MT81 (8.93 and 11.48 mg/kg day) and the 
standard  drug  5-fluorouracil52 ( 2 0  m g / k g )  w e r e  a d m i n i s t e r e d  
intraperitoneally in Groups 4, 5, 6, 7, 8, respectively for subse-
quent 7 days. After the last dose and 18 hr fasting, six mice from   
each group were sacrificed for the study of antitumor and anti-
oxidant activities and hematological parameters. The rest of the 
animals of all groups were kept for study of the tumor growth 
response and host survival.
Determination  of  tumor  growth  response  and  host  sur-
vival.  Tumor  growth  was  monitored  by  daily  weight  change 
and the survival time of host mouse by recording the mortality 
daily for 6 weeks and % ILS was calculated, Using the following 
equations53,54
MST = (Day of first death + Day of last death)/2
ILS(%) = [(Mean survival time of treated group/mean 
survival time of control group) - 1] x 100
The antitumor activity of MT81 and its structural analogues 
were determined by change in ascites tumor volume, viable and 
nonviable tumor cell count, mean survival time (MST), and per-
centage-increased life span (% ILS).
Study on normal peritoneal cells.55 Peritoneal exudate cells 
were collected after the abovementioned treatment schedule by 
repeated intraperitoneal wash with normal saline and counted 
in each of the treated groups and compared with the saline and 
vehicle control group.
Study  of  haematological  parameters.  Total  red  blood 
cell  (RBC),  white  blood  cell  (WBC)  counts  and  haemo-
globin  content  were  measured  from  freely  flowing  tail  vein 
Materials and Methods
Chemicals and reagents. All fine chemicals were obtained from 
Sigma Chemical, USA. Other chemicals used were analytical 
grade and obtained locally.
Animals. M a le a lbi no ( Sw i s s ) m ic e we i g h i n g b e t we e n 18 –25 g 
were used throughout the study. The mice were obtained from 
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